In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model

被引：146

作者：

Sun, QN

Najvar, LK

Bocanegra, R

Loebenberg, D

Graybill, JR

机构：

[1] Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis 7881, San Antonio, TX 78229 USA

[2] Beijing Union Med Univ Hosp, Dept Dermatol, Beijing 100730, Peoples R China

[3] Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2002年 / 46卷 / 07期

关键词：

D O I：

10.1128/AAC.46.7.2310-2312.2002

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The in vivo activities of posaconazole, itraconazole, and amphotericin B in neutropenic mice with zygomycosis were compared. The in vitro MICs of posaconazole and itraconazole for the strains of Mucor spp. used in this study ranged from 0.125 to 8 mug/ml and 0.25 to 8 mug/ml, respectively. The in vitro MIC range for amphotericin B is 0.125 to 0.25 mug/ml. At twice-daily doses of greater than or equal to15 mg/kg of body weight, posaconazole prolonged the survival of the mice and reduced tissue burden.

引用

收藏

页码：2310 / 2312

页数：3

相关论文

共 19 条

[1] Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts [J].

Espinel-Ingroff, A .

JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (10) :2950-2956

[2] In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole and voriconazole [J].

Gómez-López, A ;

Cuenca-Estrella, M ;

Monzón, A ;

Rodriguez-Tudela, JL .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (06) :919-921

[3] Disseminated zygomycosis in a neutropenic patient: Successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor [J].

Gonzalez, CE ;

Couriel, DR ;

Walsh, TJ .

CLINICAL INFECTIOUS DISEASES, 1997, 24 (02) :192-196

[4]

GRAYBILL JR, 1988, CURRENT THERAPY PEDI, V2

[5] Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion [J].

Herbrecht, R ;

Letscher-Bru, V ;

Bowden, RA ;

Kusne, S ;

Anaissie, EJ ;

Graybill, JR ;

Noskin, GA ;

Oppenheim, BA ;

Andrès, E ;

Pietrelli, LA .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2001, 20 (07) :460-466

[6] Zygomycosis in the 1990s in a tertiary-care cancer center [J].

Kontoyiannis, DP ;

Wessel, VC ;

Bodey, GP ;

Rolston, KVI .

CLINICAL INFECTIOUS DISEASES, 2000, 30 (06) :851-856

[7]

LUCIANO Z, 1994, J ANTIMICROB CHEMOTH, V33, P369

[8] Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis [J].

Lutz, JE ;

Clemons, KV ;

Aristizabal, BH ;

Stevens, DA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (07) :1558-1561

[9]

MCNULTY JS, 1982, LARYNGOSCOPE, V92, P1140

[10] Treatment of Absidia corymbifera infection in mice with amphotericin B and itraconazole [J].

Mosquera, J ;

Warn, PA ;

Rodriguez-Tudela, JL ;

Denning, DW .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (04) :583-586